- Novartis to acquire Avidity Biosciences for about $12 billion Reuters
- Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash CNBC
- Novartis Agrees to Acquire Avidity Biosciences for $12 Billion The Wall Street Journal
- Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis
- Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports Reuters